#Cancer therapy-related cardiac dysfunction (#CTRCD) appeared in 23% of neurofibromatosis type 1 (#NF1) patients receiving #Trametinib monotherapy in the phase 2 TRAIN trial.
Read more: https://bit.ly/4lSnxS2
#RareDisease #MedSky
1
1
0
0